CA2483464A1 - Method for treating obesity - Google Patents
Method for treating obesity Download PDFInfo
- Publication number
- CA2483464A1 CA2483464A1 CA002483464A CA2483464A CA2483464A1 CA 2483464 A1 CA2483464 A1 CA 2483464A1 CA 002483464 A CA002483464 A CA 002483464A CA 2483464 A CA2483464 A CA 2483464A CA 2483464 A1 CA2483464 A1 CA 2483464A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- anticonvulsant
- norepinephrine
- enhances
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
Claims (17)
1. A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment at least one weight-loss promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said treatment is effected.
2. The method according to claim 1 wherein said anticonvulsant is of the formula (I):
wherein X is CH2 or oxygen, R1 is hydrogen or alkyl, R2, R3, R4 and R5 are independently hydrogen or lower alkyl, and when X is CH2, R4 and R5 can be alkene groups joined to form a benzene ring and when X is oxygen, R2 and R3 and/or R4 and R5 together can be a methylenedioxy group of the following formula (II):
wherein R6 and R7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
wherein X is CH2 or oxygen, R1 is hydrogen or alkyl, R2, R3, R4 and R5 are independently hydrogen or lower alkyl, and when X is CH2, R4 and R5 can be alkene groups joined to form a benzene ring and when X is oxygen, R2 and R3 and/or R4 and R5 together can be a methylenedioxy group of the following formula (II):
wherein R6 and R7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
3. The method according to claim 2 wherein R1 is hydrogen or a C1-C4 alkyl, straight and branched chain, and R2, R3, R4, R5, R6 and R7 are a C1-C3 alkyl, straight or branched chain.
4. The method according to claim 1 wherein said anticonvulsant is of the formula (III):
wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group -CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group -CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof.
5. The method according to claim 1 wherein said anticonvulsant is zonisamide or topiramate.
6. The method according to claim 1 wherein said compound that enhances the activity of norepinephrine and/or dopamine effects said enhancement via uptake inhibition.
7. The method according to claim 1 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion, Atomoxetine or Reboxetine.
8. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered separately.
9. The method according to claim 1 wherein said anticonvulsant and said compound that enhances the activity of norepinephrine and/or dopamine are administered concurrently.
10. A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction at least one weight-loss promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine in amounts such that said reduction is effected.
11. A method of treating obesity in mammal comprising administering to a mammal in need of such treatment a compound of formula (III):
wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group -CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof, in an amount sufficient to effect said treatment.
wherein R1 is hydrogen or a halogen atom, R2 and R3 are the same or different and are each hydrogen or an alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atom, provided that the group -CH2SO2NR2R3 is bonded to the carbon atom of either of X and Y, or an alkali metal salt thereof, in an amount sufficient to effect said treatment.
12. The method according to claim 11 wherein said compound is zonisamide.
13. A composition comprising at least one weight loss-promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine.
14. The composition according to claim 13 wherein said compound is in dosage unit form.
15. The composition according to claim 14 wherein said composition is in the form of a tablet or capsule.
16. The composition according to claim 13 wherein said anticonvulsant is zonisamide or topiramate.
17. The composition according to claim 13 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38087402P | 2002-05-17 | 2002-05-17 | |
US60/380,874 | 2002-05-17 | ||
PCT/US2003/015703 WO2003097046A1 (en) | 2002-05-17 | 2003-05-19 | Method for treating obesity |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2483464A1 true CA2483464A1 (en) | 2003-11-27 |
CA2483464C CA2483464C (en) | 2011-12-20 |
Family
ID=29550030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2483464A Expired - Lifetime CA2483464C (en) | 2002-05-17 | 2003-05-19 | Method for treating obesity |
Country Status (11)
Country | Link |
---|---|
US (7) | US7109198B2 (en) |
EP (3) | EP2301537A1 (en) |
JP (1) | JP4545584B2 (en) |
KR (2) | KR101072885B1 (en) |
CN (1) | CN1320886C (en) |
AU (1) | AU2003231788B2 (en) |
CA (1) | CA2483464C (en) |
HK (1) | HK1074778A1 (en) |
MX (1) | MXPA04011203A (en) |
RU (1) | RU2341259C2 (en) |
WO (1) | WO2003097046A1 (en) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
US20190290618A1 (en) * | 2002-05-17 | 2019-09-26 | Duke University | Method for Treating Obesity |
US20190262318A1 (en) * | 2002-05-17 | 2019-08-29 | Duke University | Method for Treating Obesity |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
RU2341259C2 (en) * | 2002-05-17 | 2008-12-20 | Дюк Юниверсити | Method of obesity treatment |
US20050059718A1 (en) * | 2003-02-21 | 2005-03-17 | Hayato Miyachi | Methods of using zonisamide as an adjunctive therapy for partial seizures |
RU2350327C2 (en) * | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Compounds causing weight loss |
US20050043773A1 (en) * | 2003-08-21 | 2005-02-24 | Ivan Lieberburg | Methods of improving the safety of zonisamide therapy |
US20050043704A1 (en) * | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154032A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154033A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154034A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154037A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154036A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US7429580B2 (en) | 2004-01-13 | 2008-09-30 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
SE0400378D0 (en) * | 2004-02-17 | 2004-02-17 | Jan Hedner | Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
WO2005110405A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
US20060153934A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and magnesium |
WO2006130522A2 (en) * | 2005-05-31 | 2006-12-07 | Orexigen Therapeutics, Inc. | Methods and compositions for managing psychotic disorders |
US7884136B2 (en) | 2005-06-27 | 2011-02-08 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
AU2006279429B2 (en) | 2005-08-17 | 2010-02-25 | Hill's Pet Nutrition, Inc. | Methods and compositions for the prevention and treatment of kidney disease |
WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
WO2007047351A2 (en) * | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
BRPI0618918B8 (en) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | use of a first compound and a second compound to treat a blood glucose condition |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
WO2007062228A1 (en) * | 2005-11-28 | 2007-05-31 | Orexigen Therapeutics, Inc. | Sustained-release formulation of zonisamide |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US8088786B2 (en) * | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
RU2009116834A (en) * | 2006-11-09 | 2010-12-20 | Ориксиджен Терапьютикс, Инкорпорэйтд Сша/Сша (Us) | METHOD FOR ADMINISTRATION OF MEDICINES FOR REDUCING WEIGHT |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | Methods for treating visceral fat conditions |
WO2009152152A1 (en) * | 2008-06-09 | 2009-12-17 | Amarillo Biosciences, Inc. | Treatment of obesity with an interferon |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) * | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
US8114445B2 (en) * | 2008-11-07 | 2012-02-14 | Reliv International Inc. | Dietary supplement for promoting wellness and weight loss and methods of administering the same |
CA2750137C (en) * | 2008-12-30 | 2014-09-23 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating and preventing weight-related disorders in companion animals |
EP2515656B1 (en) * | 2009-12-21 | 2014-08-06 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
ES2762113T3 (en) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Methods of providing weight loss therapy in patients with major depression |
US8440655B2 (en) | 2010-06-21 | 2013-05-14 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
BR112014000895A2 (en) | 2011-07-15 | 2019-08-06 | Nusirt Sciences Inc | compositions and methods for modulating metabolic pathways |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
US9943517B2 (en) | 2012-11-13 | 2018-04-17 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
AU2014207707B2 (en) | 2013-01-15 | 2018-11-01 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
JP6550370B2 (en) | 2013-03-15 | 2019-07-24 | ニューサート サイエンシーズ, インコーポレイテッド | Leucine and Nicotinic Acid to Reduce Lipid Levels |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
WO2019038584A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US144174A (en) * | 1873-10-28 | Improvement in steam-engine valve-gears | ||
US143322A (en) * | 1873-09-30 | blake | ||
US9514A (en) * | 1853-01-04 | Improvement in self-winding telegraphic registers | ||
US154002A (en) * | 1874-08-11 | Improvement in electric telegraphs | ||
US2462A (en) * | 1842-02-21 | Worked buttons on the heads | ||
US254208A (en) * | 1882-02-28 | Geoegb e | ||
US215552A (en) * | 1879-05-20 | Improvement in gar-couplings | ||
US142290A (en) * | 1873-08-26 | Improvement in trimming attachments for sewing-machines | ||
US277579A (en) * | 1883-05-15 | Axle-skein | ||
US106576A (en) * | 1870-08-23 | Improvement in washing-machines | ||
US122033A (en) * | 1871-12-19 | Improvement in rotary engines | ||
US33965A (en) * | 1861-12-17 | Improvement in rifle-sights | ||
US79501A (en) * | 1868-06-30 | Jambs righey | ||
US100205A (en) * | 1870-02-22 | Improvement in furnaces | ||
US181070A (en) * | 1876-08-15 | Improvement in burglar-proof gratings | ||
US55008A (en) * | 1866-05-22 | Improved clothes-sprinkler | ||
US58293A (en) * | 1866-09-25 | Improved lady s-saddle tree | ||
US160750A (en) * | 1875-03-16 | Improvement in grain-separators | ||
US26986A (en) * | 1860-01-31 | Mortising-machine | ||
US137144A (en) * | 1873-03-25 | Improvement in stop-cocks | ||
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
BE759838A (en) | 1969-12-04 | 1971-06-03 | Wellcome Found | KETONES WITH BIOLOGICAL ACTIVITY |
US4089855A (en) * | 1976-04-23 | 1978-05-16 | Cornell Research Foundation, Inc. | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby |
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4689332A (en) * | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
NL8800823A (en) * | 1987-04-10 | 1988-11-01 | Sandoz Ag | METHOD FOR USING DOPAMINE RECEPTOR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE AGONISTS |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
WO1990013294A1 (en) | 1989-05-09 | 1990-11-15 | Whitby Research, Inc. | A method of reducing body weight and food intake using a dopamine d2 receptor agonist |
FR2657350B1 (en) | 1990-01-19 | 1992-05-15 | Centre Nat Rech Scient | COMPOUNDS FOR ENCAPSULATION IN ERYTHROCYTES - NEW DERIVATIVES OF NALOXONE AND NALTREXONE. |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) * | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
GB9217295D0 (en) * | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5358970A (en) * | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
US5541231A (en) * | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
GB9315856D0 (en) * | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
ATE214276T1 (en) * | 1994-09-19 | 2002-03-15 | Du Pont Pharm Co | COMPOSITIONS OF OPIOID ANTAGONISTS WITH SELECTIVE SEROTONIN UPtake INHIBITORS, FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE |
US5713488A (en) * | 1996-01-24 | 1998-02-03 | Farrugia; John V. | Condom dispenser |
AU724993B2 (en) * | 1996-03-13 | 2000-10-05 | Yale University | Smoking cessation treatments using naltrexone and related compounds |
US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
AU732923B2 (en) | 1996-06-28 | 2001-05-03 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
FR2758723B1 (en) | 1997-01-28 | 1999-04-23 | Sanofi Sa | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS |
DE69811378T2 (en) * | 1997-10-03 | 2004-02-12 | Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | COMPOSITIONS FOR TREATING NICOTINE DEPENDENCY, CONTAINING MECAMYLAMINE AND BUPROPION |
US6262049B1 (en) * | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Pharmaceutical compositions containing piperazinyl-heterocyclic compounds for treating psychiatric disorders |
CA2317044C (en) * | 1997-12-26 | 2008-02-26 | Dainippon Pharmaceutical Co., Ltd. | Medicament for neurodegenerative diseases |
EP1829544A1 (en) | 1998-01-21 | 2007-09-05 | Glaxo Group Limited | Pharmaceutically active morpholinol |
AU2483599A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US6048322A (en) * | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
US6323236B2 (en) * | 1999-02-24 | 2001-11-27 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US6210716B1 (en) * | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6267995B1 (en) | 1999-03-03 | 2001-07-31 | Pure World Botanicals, Inc. | Extract of Lepidium meyenii roots for pharmaceutical applications |
ATE384035T1 (en) | 1999-04-01 | 2008-02-15 | Esperion Therapeutics Inc | ETHER COMPOUNDS, COMPOSITIONS AND THEIR USE |
EP1905757A1 (en) | 1999-04-06 | 2008-04-02 | Sepracor Inc. | Derivatives of Venlafaxine and methods of preparing and using the same |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
EP2305226B1 (en) | 1999-06-14 | 2015-05-06 | Vivus, Inc. | Combination therapy for the treatment of sleep apnea associated with obesity |
US7056890B2 (en) | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
HUP0201623A3 (en) * | 1999-07-01 | 2004-12-28 | Upjohn Co | Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system |
US6071918A (en) * | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
CN1406129A (en) * | 2000-01-22 | 2003-03-26 | 艾伯特·舒尔曼 | Methods for the treatment of substance abuse |
US20020090615A1 (en) * | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
ATE326222T1 (en) * | 2000-03-15 | 2006-06-15 | Wolfgang Sadee | NALOXONE AND NALTREXONE ANALOGUES IN DRUG ABUSE TREATMENT |
US6437147B1 (en) * | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US6627653B2 (en) * | 2000-08-02 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
JP5161412B2 (en) * | 2000-09-18 | 2013-03-13 | サノス・バイオサイエンス・アクティーゼルスカブ | Methods of using GLP-1 and GLP-2 peptides |
RU2003112618A (en) * | 2000-10-30 | 2004-09-27 | Орто-Макнейл Фармасьютикал, Инк. (Us) | COMBINED THERAPY, INCLUDING ANTI-DIABETIC AND ANTI-ANTI-VEHICLES |
US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US20030087896A1 (en) * | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US6481031B1 (en) * | 2001-11-14 | 2002-11-19 | In Mo Hwang | Pillow oriented for comfort in varying sleeping positions |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
RU2341259C2 (en) | 2002-05-17 | 2008-12-20 | Дюк Юниверсити | Method of obesity treatment |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
AU2003253925A1 (en) | 2002-07-18 | 2004-02-09 | Banyu Pharmaceutical Co., Ltd. | Combination therapy for the treatment of obesity |
US7273884B2 (en) | 2002-09-13 | 2007-09-25 | Eisai, Inc. | Method of treating tremors |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
RU2350327C2 (en) | 2003-04-29 | 2009-03-27 | Ориксиджен Серапьютикс, Инкорпорэйтд | Compounds causing weight loss |
WO2004110368A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
US20060148721A1 (en) | 2003-06-06 | 2006-07-06 | Erondu Ngozi E | Combination therapy for the treatment of dyslipidemia |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
US7759358B2 (en) | 2003-07-23 | 2010-07-20 | Crooks Peter A | Oral bioavailable prodrugs |
KR100965580B1 (en) * | 2003-08-21 | 2010-06-23 | 엘지디스플레이 주식회사 | Liquid crystal display apparatus and driving method thereof |
WO2005049043A1 (en) | 2003-11-18 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising metformin and anticonvulsant agents |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US7429580B2 (en) | 2004-01-13 | 2008-09-30 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US20060100205A1 (en) | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
WO2005110405A1 (en) | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
BRPI0514060A (en) | 2004-08-03 | 2008-05-27 | Orexigen Therapeutics Inc | combination of bupropion and a second weight loss compound |
WO2006055854A2 (en) * | 2004-11-17 | 2006-05-26 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtazapine treatment |
US7346233B2 (en) * | 2005-02-14 | 2008-03-18 | Corning Incorporated | Single mode (SM) fiber optical reader system and method for interrogating resonant waveguide-grating sensor(s) |
-
2003
- 2003-05-19 RU RU2004131636/14A patent/RU2341259C2/en active
- 2003-05-19 CN CNB038112299A patent/CN1320886C/en not_active Expired - Lifetime
- 2003-05-19 MX MXPA04011203A patent/MXPA04011203A/en active IP Right Grant
- 2003-05-19 KR KR1020047018476A patent/KR101072885B1/en active IP Right Grant
- 2003-05-19 CA CA2483464A patent/CA2483464C/en not_active Expired - Lifetime
- 2003-05-19 EP EP10185789A patent/EP2301537A1/en not_active Ceased
- 2003-05-19 EP EP16178084.6A patent/EP3173082A1/en not_active Withdrawn
- 2003-05-19 EP EP03753096.1A patent/EP1505967B1/en not_active Expired - Lifetime
- 2003-05-19 AU AU2003231788A patent/AU2003231788B2/en not_active Expired
- 2003-05-19 WO PCT/US2003/015703 patent/WO2003097046A1/en active Application Filing
- 2003-05-19 US US10/440,404 patent/US7109198B2/en not_active Expired - Lifetime
- 2003-05-19 JP JP2004505045A patent/JP4545584B2/en not_active Expired - Fee Related
- 2003-05-19 KR KR1020117003379A patent/KR20110043664A/en not_active Application Discontinuation
-
2004
- 2004-04-23 US US10/830,071 patent/US7425571B2/en not_active Expired - Lifetime
-
2005
- 2005-02-15 US US11/058,981 patent/US20050137144A1/en not_active Abandoned
- 2005-02-15 US US11/059,027 patent/US20050143322A1/en not_active Abandoned
- 2005-08-15 HK HK05107036.6A patent/HK1074778A1/en not_active IP Right Cessation
- 2005-09-07 US US11/222,135 patent/US20060009514A1/en not_active Abandoned
-
2006
- 2006-05-05 US US11/381,990 patent/US20080188476A1/en not_active Abandoned
-
2008
- 2008-09-05 US US12/205,769 patent/US7754748B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050143322A1 (en) | 2005-06-30 |
KR101072885B1 (en) | 2011-10-17 |
US7109198B2 (en) | 2006-09-19 |
MXPA04011203A (en) | 2005-07-14 |
HK1074778A1 (en) | 2005-11-25 |
US20040033965A1 (en) | 2004-02-19 |
US20060009514A1 (en) | 2006-01-12 |
KR20050023265A (en) | 2005-03-09 |
US20080188476A1 (en) | 2008-08-07 |
CA2483464C (en) | 2011-12-20 |
AU2003231788A1 (en) | 2003-12-02 |
US20080319036A1 (en) | 2008-12-25 |
EP3173082A1 (en) | 2017-05-31 |
CN1320886C (en) | 2007-06-13 |
RU2004131636A (en) | 2005-06-27 |
KR20110043664A (en) | 2011-04-27 |
WO2003097046A1 (en) | 2003-11-27 |
US7425571B2 (en) | 2008-09-16 |
EP1505967A1 (en) | 2005-02-16 |
US7754748B2 (en) | 2010-07-13 |
EP1505967A4 (en) | 2007-09-05 |
JP2005530782A (en) | 2005-10-13 |
EP1505967B1 (en) | 2016-07-13 |
CN1652778A (en) | 2005-08-10 |
RU2341259C2 (en) | 2008-12-20 |
AU2003231788B2 (en) | 2008-09-11 |
EP2301537A1 (en) | 2011-03-30 |
JP4545584B2 (en) | 2010-09-15 |
US20050137144A1 (en) | 2005-06-23 |
US20040198668A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2483464A1 (en) | Method for treating obesity | |
JP2004524312A5 (en) | ||
EP2335734A3 (en) | Treatment of pain and other alpha 2 adrenergic-mediated conditions | |
RU2003100076A (en) | ANTI-CURRENT DERIVATIVES USED TO PREVENT DEVELOPMENT OF DIABETES AND SYNDROME X | |
MY157828A (en) | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions | |
CA2430692A1 (en) | Geldanamycin derivative and use of same to treat cancer | |
WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
TW200621233A (en) | HCV NS3-NS4A protease inhibition | |
SG149814A1 (en) | Compositions and methods for treating diabetes | |
MXPA05010873A (en) | Methods for treatment of parkinson's disease. | |
CA2620065A1 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
MXPA04001643A (en) | (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor. | |
CA2439838A1 (en) | (2-hydroxy)ethyl-thioureas useful as modulators of alpha2b adrenergic receptors | |
CA2617817A1 (en) | Thiazole derivatives for treating or preventing sleep disorders | |
MX2012000488A (en) | Combination therapy for the treatment of diabetes. | |
RU2008133654A (en) | METHOD AND MEDICINE FOR TREATMENT OF SEVERE HEART FAILURE | |
CO5200778A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A THERAPEUTICALLY EFFECTIVE AMOUNT OF B ENZIMIDAZOL, ADMINISTERED TO PREVENT AND TREAT CANCER AND INHIBIT METASTASIS | |
DE60238391D1 (en) | AZOLE AS MALONYL-COA DECARBOXYLASE HEMMER USES AS MODULATORS OF METABOLISM | |
RU2002133868A (en) | CANNABINOID MEDICINES | |
JP2005512965A5 (en) | ||
FI3164125T3 (en) | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | |
CA2525373A1 (en) | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | |
JP2004525905A5 (en) | ||
EA200600626A1 (en) | COMPOSITION AND MEDICATION FORM OF LOW DUCTED LONGIODOPA | |
ZA200502681B (en) | Transdermal administration of (R)-3,3-diphenylpropylamine monoesters. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20230519 |